UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
-------------------------
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
March 14,
2005
(Date of
earliest event reported)
DOR
BIOPHARMA, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
1-14778
41-1505029
(State or
Other Jurisdiction of Incorporation)
(Commission File No.) (IRS
Employer Identification No.)
Lincoln
Building, 1691 Michigan Avenue Miami, FL 33139
(Address
of Principal Executive Offices)
(305)
534-3383
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instructions A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02. Results
of Operations and Financial Condition.
On
March 14, 2005, DOR BioPharma, Inc. issued a press release announcing its
results of operations for the fourth quarter of 2004. A copy of the press
release is attached as Exhibit 99 to this report. This information is not
deemed to be “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934 and is not incorporated by reference into any Securities
Act registration statements.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
99 Press
release issued by DOR BioPharma, Inc. on March 14, 2005.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By: /s/
Michael T. Sember
Name:
Michael
T. Sember
Title:
President and Chief Executive Officer
Date:
March 14, 2005
EXHIBIT
INDEX
Exhibit Description
99 Press
release issued by DOR BioPharma, Inc. on March 14, 2005.